一品红药业集团股份有限公司 独立董事 2024 年度述职报告 （杨德明已离任） 尊敬的各位股东及股东代表： 本人作为一品红药业集团股份有限公司（以下简称"公司"）第三届董事会 的独立董事，严格按照《公司法》《上市公司独立董事管理办法》《上市公司自律 监管指引第 2 号——创业板上市公司规范运作》等有关法律法规、规范性法律文 件以及《公司章程》《独立董事工作制度》等公司相关的规定和要求，忠实履行 独立董事的职责，勤勉尽责，积极出席公司相关会议，认真审议董事会各项议案， 审慎决策，对公司重大事项发表意见，充分发挥独立董事的独立性和专业性作用， 及时了解公司的生产经营信息，全面关注公司的发展状况，促进公司规范运作， 切实维护公司和全体股东特别是中小股东的合法权益。 2024 年 7 月，本人任期届满，不再担任公司董事会独立董事及董事会专门 委员会相关职务，现将本人 2024 年度履行独立董事职责的情况汇报如下： 一、独立董事基本情况 本人杨德明，男，中国国籍，无境外永久居留权，1975 年出生，博士学历， 现任暨南大学教授、博士生导师，兼任广东开平农村商业银行股份有限公司独立 董事（非上市公司）和广东芳源环保股份有 ...

一品红药业集团股份有限公司 独立董事 2024 年度述职报告 （胡咸华） 尊敬的各位股东及股东代表： 二、年度履职情况 （一）出席董事会、股东大会情况 2024 年，本人出席董事会、股东大会的情况如下： | 独立董事 | 报告期应 | 现场出席 | 以通讯方 | 委托出席 | 缺席董事 | 出席股东 | | --- | --- | --- | --- | --- | --- | --- | | 姓名 | 参加董事 | 董事会 | 式参加董 | 董事会 | 会次数 | 大会次数 | | | 会次数 | 次数 | 事会次数 | 次数 | | | | 胡咸华 | 5 | 5 | 0 | 0 | 0 | 3 | 作为一品红药业集团股份有限公司（以下简称"公司"）第四届董事会的独 立董事，本人严格按照《公司法》《上市公司独立董事管理办法》《上市公司自律 监管指引第 2 号——创业板上市公司规范运作》等有关法律法规、规范性法律文 件以及《公司章程》《独立董事工作制度》等公司相关的规定和要求，忠实履行 独立董事的职责，勤勉尽责，积极出席公司相关会议，认真审议董事会各项议案， 审慎决策，对公司重大事项发表意见，充分发挥独立董 ...

| 持有数量(万股) 名称 | | 占总股本比例 | 增减情况(万 | | --- | --- | --- | --- | | | | (%) | 股) | | 广东广润集团有限公司 | 18360.00 | 43.96 | 不变 | | 吴美容 | 2548.66 | 6.10 | 不变 | | 广州市福泽投资管理中心(有限合伙) | 2430.00 | 5.82 | 不变 | | 吴春江 | 2177.88 | 5.21 | 不变 | | 陈丹娜 | 908.28 | 2.17 | 不变 | | 李捍雄 | 621.00 | 1.49 | 新进 | | 中国工商银行股份有限公司-广发多因子灵活配混合型 证券投资基金 | 596.30 | 1.43 | 新进 | | 一品红（300723）药业股份有限公司-2024年员工持股 | | | | | 计划 | 511.61 | 1.22 | 新进 | | 广州南沙阳光金瑞投资有限公司 | 487.02 | 1.17 | -29.92 | | 全国社保基金五零三组合 | 400.00 | 0.96 | 新进 | | 较上个报告期退出前十大股东有 | | | | | ...

Financial Performance - The company's operating revenue for 2024 was ¥1,450,230,295.28, a decrease of 42.07% compared to ¥2,503,447,004.47 in 2023[23]. - The net profit attributable to shareholders for 2024 was -¥540,038,956.70, representing a decline of 392.52% from ¥184,613,302.81 in 2023[23]. - The cash flow from operating activities for 2024 was -¥550,424,562.17, a decrease of 220.17% compared to ¥458,051,312.80 in 2023[23]. - The basic earnings per share for 2024 was -¥1.1956, down 392.54% from ¥0.4087 in 2023[23]. - The total assets at the end of 2024 were ¥4,404,103,484.82, a slight decrease of 0.03% from ¥4,405,295,590.95 at the end of 2023[23]. - The net assets attributable to shareholders at the end of 2024 were ¥1,878,454,901.15, down 25.52% from ¥2,522,087,479.40 at the end of 2023[23]. - The company reported a significant decline in net profit after deducting non-recurring gains and losses, which was -¥288,936,321.54 for 2024 compared to ¥119,978,271.81 in 2023, a drop of 340.82%[23]. - The company's revenue after deducting unrelated business income for 2024 was ¥1,418,927,617.26, compared to ¥2,480,622,403.37 in 2023[23]. - The company achieved a revenue of 145,023.03 million yuan, a year-on-year decrease of 42.07%[55]. - The net profit attributable to shareholders was CNY -540.04 million, a year-on-year decline of 392.52%[55]. Research and Development - The company has increased its investment in research and development, with R&D expenses accounting for over 20% of revenue. The innovative drug AR882 has entered the Phase III clinical stage domestically and internationally[4]. - The company is committed to enhancing its innovative drug development capabilities through various mechanisms, including independent and collaborative research[5]. - The company has a total of 15 innovative drugs in its R&D pipeline, including AR882 for hyperuricemia and APH01727 for diabetes and weight loss, both currently in clinical trials[45]. - The company has established a complete R&D system for chronic disease drugs, with 29 ongoing projects, including global innovative drugs AR882 and APH01727, and holds 65 registered chronic disease drug approvals[52]. - The company has established multiple specialized R&D centers, including those for innovative drugs and high-end generics, enhancing its innovation capabilities[68]. - The company has a dedicated R&D team of 338 personnel, supported by a global network of scientific advisors to enhance innovation[73]. - The company has implemented a digital management platform for R&D, which has won the 2023 National Pharmaceutical Industry Excellent Digital Case Award[92]. - The company has 71 ongoing research projects based on its R&D technology platform, excluding technology transformation projects[93]. - The company has initiated clinical trials for new chronic disease medications, such as AR882 capsules and APH01727 tablets, indicating a commitment to innovation in this sector[129]. Market and Product Development - The company is focused on the development of innovative drugs and children's medications, aligning with the growing demand for high-quality healthcare solutions in the market[32]. - In 2024, the company's revenue from pediatric drugs reached 936 million yuan, accounting for 66.71% of its pharmaceutical manufacturing business revenue[40]. - The company holds a total of 26 pediatric drug registration approvals as of the report date[40]. - The company generated 370 million yuan in revenue from chronic disease drugs in 2024, representing 26.36% of its pharmaceutical manufacturing business revenue[42]. - The number of approved pediatric drugs increased significantly, with 106 new varieties approved during the reporting period, including 20 (18.9%) that expedited through priority review[37]. - The company has 65 registered products in the chronic disease drug category as of the report date[42]. - The pediatric drug market is expected to experience rapid growth due to increased government support and a focus on suitable formulations for children[40]. - The company is actively expanding its sales channels, including new retail channels such as chain KA and internet marketing[67]. - The company has received production approval for multiple new products, including APRD-H162 and APRD-H186, expanding its product categories in both chronic and pediatric medications[128]. Regulatory and Compliance - The company emphasizes strict adherence to GMP and GSP requirements in its production and distribution processes to ensure product quality[7]. - The company has maintained a good track record in product quality, with no major quality incidents reported, but acknowledges potential risks as it expands its operational scale[7]. - The company is closely monitoring industry policy changes that may impact its operational model and competitive landscape, leveraging its full industry chain layout to respond proactively[170]. - The company has not engaged in any securities or derivative investments during the reporting period[146][147]. - The company has not provided guarantees for its controlling shareholders, ensuring no misuse of company funds[177]. Governance and Management - The company emphasizes a governance structure that ensures effective checks and balances among shareholders, the board, and management, promoting transparency and shareholder rights[176]. - The company has established four specialized committees under the board, with independent directors constituting two-thirds of the members in each committee, enhancing decision-making quality[178]. - The company respects and protects the rights of stakeholders, focusing on social responsibility and communication[179]. - The company has a structured remuneration policy that considers operational performance and individual capabilities[191]. - The board of directors consists of 5 members, including 2 independent directors, complying with legal and regulatory requirements[178]. - The company has conducted multiple shareholder meetings in 2024, with participation rates ranging from 59.98% to 66.69%[181]. - The company is preparing for a governance transition with upcoming elections for board and supervisory roles scheduled for July 18, 2024[183]. Strategic Focus - The company aims to enhance its innovation capabilities by focusing on children's medication and chronic disease treatments, leveraging advanced drug development technologies[160]. - The company plans to optimize its innovation system and R&D platforms to strengthen its core competitiveness, with a focus on key projects like AR882 and APH01727[164]. - The company plans to enhance its digital operations through projects like SAP digital operation and WMS automation, aiming for efficient and intelligent management[105]. - The company is actively investing in research and technology services, with a focus on strategic emerging industries[156]. - The company aims to expand its market share through mergers and acquisitions in the pharmaceutical and biotechnology sectors[156].

一品红药业集团股份有限公司 2025 年第一季度报告 证券代码：300723 证券简称：一品红 公告编号：2025-022 一品红药业集团股份有限公司 2025 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 一品红药业集团股份有限公司 2025 年第一季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经过审计 □是 否 1 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | | --- | --- | --- | --- | --- | | | | | （%） | | | 营业收入（元） | 376,961,180.39 | 622,870,629.55 | | -39.4 ...

证券研究报告|公司动态点评 2025 年 04 月 21 日 一品红（300723.SZ） AR882 全球 III 期临床稳步推进，BIC 药物潜力凸显 | 财务指标 | 2022A | 2023A | 2024E | 2025E | 2026E | 2027E 增持（首次评级） | | | --- | --- | --- | --- | --- | --- | --- | --- | | 营业收入（百万元） | 2,280 | 2,503 | 1,618 | 1,973 | 2,251 | 股票信息 | | | 增长率 yoy（%） | 3.7 | 9.8 | -35.4 | 21.9 | 14.1 | | | | 归母净利润（百万元） | 291 | 185 | -575 | 262 | 360 | 行业 | 医药 | | 增长率 yoy（%） | -5.3 | -36.5 | - | 145.6 | 37.4 | 2025 年 4 月 18 日收盘价（元） | 36.95 | | ROE（%） | 12.1 | 5.8 | -27.1 | 10.9 | 13.1 | 总市值（百万元） | 16,690 ...

记者4月19日从一品红（300723）获悉，公司痛风创新药AR882全球Ⅲ期临床试验REDUCE2试验近期已 完成全部患者入组，意味着AR882国内及国外临床试验全面进入关键性Ⅲ期阶段。AR882项目研发相关 负责人向记者介绍称，目前AR882已完成的全球多中心Ⅱ期临床试验数据显示，与现有疗法相比， AR882治疗痛风患者的疗效更显著，安全性更高。AR882除了能降低痛风患者的sUA水平，还能显著减 少痛风石、减轻尿酸结晶负担及降低痛风急性发作率。这一成果不仅填补了全球痛风石溶解疗法的空 白，也被国家药监局大湾区分中心列为重点品种。(上海证券报) ...

在下会议那一条的话是我们在去年的这个年底啊我们就挖掘出来在创效这个新闻里面非常具有特色的一个啊公司啊因为当时体量还不大不到一百亿啊然后呢呃我们觉得他的这个啊传统的业务啊经过了二零二四年各种数位的因素的这个影响啊啊确实已经到底部了啊然后呃在创效又这个层面上呢我觉得市场对他的认知和理解还有比较大的这个呃偏差 然后另外呢今年的话其实是从他的这个一二八八二是这个最核心的评论来看呢我认为是一个啊临床实验数据啊持续兑现的这样一个时间节点啊对于大家去理解这个评论的价值那也会有更为啊这个切身的这个感受啊可能之前大家觉得太远了他尽量的对数据的读书啊会让大家对这个评论有更深的理解啊他当然公司本身的啊缺乏解放是比较多啊就尽量的话我们也是请我们团队的这个 同事张雪在就一品红给大家做一个深入的汇报那我们在上周的话上周五也是发布了这个一品红的深度报告最近呢现在公司的股价表现非常亮眼所以呢接下来我们请张雪给大家对于一品红这个系统的这个介绍和推荐张雪您先可以开始 各位投资者晚上好,今天我们来汇报一下我们这一期重点推荐的疫情红的深度报告。其实这个报告主要还是从公司在创新研发聚焦在通风领域,并且AI882这个产品已经在全球和国内已经开展了3D银 ...

证券代码：300723 证券简称：一品红 公告编号：2025-017 一品红药业集团股份有限公司 2、公司《2024 年年度报告》和《2025 年第一季度报告》预计将于 2025 年 4 月 25 日披露，请投资者注意投资风险。公司已于 2025 年 1 月 23 日披露了《2024 年度业绩预告》，预计净利润为负值，出现亏损。公司 2024 年度归属于上市公司 股东的净利润预计亏损 47,226.04 万元–67,959.42 万元，归属于上市公司股东 的扣除非经常性损益后的净利润预计亏损 24,086.05 万元–34,660.41 万元（上 述数据未经审计）。截止目前，公司不存在应修正情况，也不存在应披露而未披 露的重大信息。 3、公司合作在研创新药 AR882 尚需在国内外开展Ⅲ期临床研究并经药品审 评部门审批通过后，方可上市销售,能否通过监管部门的最终批准、获批上市及 上市时间具有不确定性。AR882 目前尚未实现上市销售，未产生销售收入，对公 司近期业绩不会产生重大影响。敬请广大投资者理性投资，注意风险。 4、经公司自查，并向公司控股股东、实际控制人核实，截至本公告披露日， 确认不存在应披露而未披 ...

一品红：AR882目前尚未实现上市销售 未产生销售收入 智通财经4月14日电，一品红(300723.SZ)发布异动，公司合作在研创新药AR882尚需在国内外开展Ⅲ期 临床研究并经药品审评部门审批通过后，方可上市销售，能否通过监管部门的最终批准、获批上市及上 市时间具有不确定性。AR882目前尚未实现上市销售，未产生销售收入，对公司近期业绩不会产生重大 影响。敬请广大投资者理性投资，注意风险。 ...